<DOC>
	<DOCNO>NCT02775617</DOCNO>
	<brief_summary>This open-label prospective community intervention trial assess impact community mass treatment azithromycin yaw ivermectin scabies , non-yaws bacterial skin infection . Communities randomise receive standard treatment yaw scabies either parallel ( site 1 ) sequence ( site 2 ) . Treatment yaw : Single dose Azithromycin ( 30mg/kg , max 2G ) . Treatment scabies : Either oral dose Ivermectin ( 200Î¼g/kg ) permethrin cream contraindication Ivermectin ( WT &lt; 15kg , pregnant breastfeed woman ) give 2 dos 7-14 day apart . Investigators complete clinical microbiological assessment bacterial skin disease baseline 12 month assess impact treatment prevalence bacterial infection emergence antimicrobial resistance . Primary Outcome 1 . Difference change prevalence impetigo baseline 12- month parallel sequential treatment arm . Secondary Outcomes 2 . Change proportion swab sample S. pyogenes culture baseline follow-up two arm 3 . The proportion sample drug-resistant isolate S.pyogenes culture two arm</brief_summary>
	<brief_title>Azithromycin - Ivermectin Mass Drug Administration Skin Disease</brief_title>
	<detailed_description />
	<mesh_term>Scabies</mesh_term>
	<mesh_term>Impetigo</mesh_term>
	<mesh_term>Ivermectin</mesh_term>
	<mesh_term>Permethrin</mesh_term>
	<criteria>All community member able include study . Allergy component allocate drug regimen</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>